Also trades as: HEMO.L (LSE) · $vol 0M
HOPHF OTC
Hemogenyx Pharmaceuticals Plc
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -97.1%
5Y: -80.1%
$2.33
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$800K
+0.0% ▲
Operating Income
-$7M
-110707.9% ▼
Net Income
-$6M
-83885.2% ▼
EPS (Diluted)
$-2.13
+10.1% ▲
EBITDA
-$5M
-96400.4% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $351K | $284K | $3M | $0 | $800K |
| Gross Profit | -$351K | -$284K | -$3M | $0 | -$800K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $114 | $51 | $487 | $91 | $237K |
| SG&A Expenses | $628K | $1M | $942K | $5K | $5M |
| Operating Expenses | $2M | $3M | $3M | $6K | $6M |
| Operating Income | -$2M | -$3M | $4M | -$6K | -$7M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $33K | $3M | $33 | $231 | $340K |
| Income Before Tax | -$2M | -$5M | -$4M | -$7K | -$7M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$2M | -$5M | -$4M | -$7K | -$6M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-2.01 | $-2.64 | $-1.62 | $-2.37 | $-2.13 |
| EBITDA | -$2M | -$3M | -$5M | -$5K | -$5M |
| Shares Outstanding | 1037 | 1935 | 2449 | 2823 | 3M |